Sugi Predict

Sugi Predict / Compounds / SCHEMBL14636624

SCHEMBL14636624

SCHEMBL14636624

CC1COC(CO)CN1C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.42
▸ GPR119 Q8TDV5 4/20 0.36
▸ TSHR P16473 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22079229 1.00 NR1H2 (0.42) NR1H2GPR119TSHRALDH1A1USP2
SCHEMBL30427255 1.00 NR1H2 (0.42) NR1H2GPR119TSHRALDH1A1USP2
SCHEMBL29017250 1.00 NR1H2 (0.42) NR1H2GPR119TSHRALDH1A1USP2
SCHEMBL14636625 1.00 NR1H2 (0.42) NR1H2GPR119TSHRALDH1A1USP2
SCHEMBL15920678 1.00 NR1H2 (0.42) NR1H2GPR119TSHRALDH1A1USP2
SCHEMBL20051537 1.00 NR1H2 (0.42) NR1H2GPR119TSHRALDH1A1USP2
SCHEMBL19787506 0.89 NR1H2 (0.38) NR1H2GPR119TSHRALDH1A1USP2
SCHEMBL19787492 0.89 NR1H2 (0.38) NR1H2GPR119TSHRALDH1A1USP2
SCHEMBL22943928 0.88 ALDH1A1 (0.37) NR1H2GPR119TSHRALDH1A1USP2
SCHEMBL19341343 0.88 ALDH1A1 (0.37) NR1H2GPR119TSHRALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695259-A1 TRICYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2026-02-18 — — EP disclosed
WO-2024213610-A1 TRICYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2024-10-17 — — WO disclosed
EP-3365335-B1 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES ARRAY BIOPHARMA INC (US) 2024-02-14 — — EP disclosed
US-20230406851-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2023-12-21 — — US disclosed
CN-116075514-A Pharmacologically active heterocyclic substituted pyrazolo [1,5-a ] pyrimidine derivatives 吉瑞工厂 2023-05-05 — — CN disclosed
EP-3998267-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF Bellus Health Cough Inc. (CA) 2022-05-18 — — EP disclosed
US-20220062290-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2022-03-03 — — US disclosed
EP-3381917-B1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF BELLUS HEALTH COUGH INC (CA) 2021-09-08 — — EP disclosed
EP-3381917-B1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF BELLUS HEALTH COUGH INC (CA) 2021-09-08 — — EP disclosed
US-20210228588-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2021-07-29 — — US disclosed
US-20170143730-A1 Imidazopyridine Compounds and Uses Thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2017-05-25 — — US disclosed
WO-2017070708-A1 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES ARRAY BIOPHARMA, INC. (US) 2017-04-27 — — WO disclosed
US-9598409-B2 Imidazopyridine compounds and uses thereof NEOMED INSTITUTE (CA) 2017-03-21 — — US disclosed
US-20170008899-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-01-12 — — US disclosed
US-20150361078-A1 Imidazopyridine Compounds and Uses Thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2015-12-17 — — US disclosed
EP-2951177-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF Neomed Institute (CA) 2015-12-09 — — EP disclosed
WO-2014117274-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NEOMED INSTITUTE (CA) 2014-08-07 — — WO disclosed
US-20140221333-A1 BTK INHIBITORS MERCK SHARP & DOHME B.V. (NL) 2014-08-07 — — US disclosed
EP-2734529-A1 BTK INHIBITORS Merck Sharp & Dohme Corp. (US) 2014-05-28 — — EP disclosed
WO-2013010380-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-01-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230406851-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NISCH, ABL1, PAICS NR1H2 4746/4885GPR119 1647/4885TSHR 2818/4885
US-20170008899-A1 BTK INHIBITORS BTK, SYK, ABL1 NR1H2 2698/4885GPR119 3307/4885TSHR 1717/4885
US-20150361078-A1 Imidazopyridine Compounds and Uses Thereof NISCH, ABL1, PAICS NR1H2 4746/4885GPR119 1647/4885TSHR 2818/4885
US-20220062290-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NISCH, ABL1, PAICS NR1H2 4746/4885GPR119 1647/4885TSHR 2818/4885
US-20170143730-A1 Imidazopyridine Compounds and Uses Thereof NISCH, ABL1, PAICS NR1H2 4746/4885GPR119 1647/4885TSHR 2818/4885
US-20140221333-A1 BTK INHIBITORS BTK, SYK, ABL1 NR1H2 2903/4885GPR119 3560/4885TSHR 1994/4885
US-20210228588-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NISCH, ABL1, PAICS NR1H2 4746/4885GPR119 1647/4885TSHR 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.